Evidence map›Paper›PMID 35011228›Full record

ArticleAnimals : an open access journal from MDPI2022

Owner-Perception of the Effects of Two Long-Lasting Dog-Appeasing Pheromone Analog Devices on Situational Stress in Dogs.

Céline S Nicolas, Gemma Espuña, Aurélie Girardin, Jaume Fatjó, Jonathan Bowen, Patricia Monginoux

Abstract read
In one paragraph

Article in Animals : an open access journal from MDPI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Céline S NicolasGlobal Marketing & Market Development Department, Virbac, 13e rue LID, 06511 Carros, France.ORCID 0000-0002-5285-5946
Gemma EspuñaGlobal Marketing & Market Development Department, Virbac, 13e rue LID, 06511 Carros, France.
Aurélie GirardinResearch & Development Petcare Department, Virbac, 13e rue LID, 06511 Carros, France.
Jaume FatjóEthometrix Ltd., 168 Church Road, East Sussex BN3 2DL, UK.
Jonathan BowenEthometrix Ltd., 168 Church Road, East Sussex BN3 2DL, UK.
Patricia MonginouxResearch & Development Petcare Department, Virbac, 13e rue LID, 06511 Carros, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Devices that release a synthetic analog of the canine-appeasing pheromone can help to relax dogs during stressful situations, but they usually last for only one month. Two new devices with this analog were tested by owners of dogs showing signs of stress in a range of everyday situations: Zenidog™ collar, lasting three months, and Zenidog™ diffusing gel, lasting two months (Virbac, Carros, France). They were compared against reference products that last for one month. In the three-month study with collars, one group received Zenidog™ collar, one received the reference collar, and one group of dogs wore an antiparasitic collar alongside a Zenidog™ collar. In the two-month study with diffusers, groups received either the unpowered Zenidog™ gel diffuser or the reference electric diffuser. Owners regularly completed a questionnaire that assessed seventeen general behaviors and sources of fear and eleven specific signs of stress. Global scores for these two main scales were calculated, and the evolution of scores was compared between groups. Non-parametric tests with a Bonferroni correction were used for statistical analysis. An improvement of all global scores was observed in all groups (

Indexed as

appeasing pheromonebehavioral scalesdiffusing geldog’s behaviorlong-lasting collarrelaxingsigns of stresssources of fearstressZenidog

Identifiers

PMID35011228
PMCPMC8749783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.